Identification of lead CD24 scFvs for integration into CAR T-cell therapy

CD24 is a heavily glycosylated surface protein reportedly expressed across a broad range of solid and hematological malignancies, making it an attractive candidate antigen for chimeric antigen receptor (CAR) T-cell therapy. Using publicly available datasets, we confirmed that CD24 is broadly expressed across tumor types and, in a single CD19-negative relapse of B-cell acute lymphoblastic leukemia, remained expressed after CD19 CAR T-cell therapy. Thus, CD24 has potential both as a pan-cancer target and as a second-line or combinatorial target following antigen escape. Notably, the antigen recognition domain of the CAR, typically a single chain variable fragment (scFv) of an antibody, is a critical determinant of CAR specificity and function. We here, therefore, performed a head-to-head comparison of four CD24 second-generation 4-1BB CAR T-cells differing only in their scFv clone, specifically clones H2L3, SWA11 and GB7011–05 recognizing the protein core of CD24 and clone SN3 recognizing a CD24 glyco-epitope. The H2L3-derived CAR T-cells displayed high basal IFN-γ production whereas the SWA11-derived CAR T-cells were cytotoxic against cell lines with undetectable CD24 expression. The SN3- and GB7011–05 derived CARs were CD24-specific, and phenotypically equivalent, making them both promising candidates for further exploitation.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1989845
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identification of lead CD24 scFvs for integration into CAR T-cell therapy

Maria Lysandrou, Edwin Bremer, Jimena Álvarez Freile, Douwe Freerk Samplonius
1 links
Frontiers in Immunology
CAR-T cell therapy research
article

Identification of lead CD24 scFvs for integration into CAR T-cell therapy

Maria Lysandrou, Edwin Bremer, Jimena Álvarez Freile, Douwe Freerk Samplonius
article en

Abstract

CD24 is a heavily glycosylated surface protein reportedly expressed across a broad range of solid and hematological malignancies, making it an attractive candidate antigen for chimeric antigen receptor (CAR) T-cell therapy. Using publicly available datasets, we confirmed that CD24 is broadly expressed across tumor types and, in a single CD19-negative relapse of B-cell acute lymphoblastic leukemia, remained expressed after CD19 CAR T-cell therapy. Thus, CD24 has potential both as a pan-cancer target and as a second-line or combinatorial target following antigen escape. Notably, the antigen recognition domain of the CAR, typically a single chain variable fragment (scFv) of an antibody, is a critical determinant of CAR specificity and function. We here, therefore, performed a head-to-head comparison of four CD24 second-generation 4-1BB CAR T-cells differing only in their scFv clone, specifically clones H2L3, SWA11 and GB7011–05 recognizing the protein core of CD24 and clone SN3 recognizing a CD24 glyco-epitope. The H2L3-derived CAR T-cells displayed high basal IFN-γ production whereas the SWA11-derived CAR T-cells were cytotoxic against cell lines with undetectable CD24 expression. The SN3- and GB7011–05 derived CARs were CD24-specific, and phenotypically equivalent, making them both promising candidates for further exploitation.

Frontiers in ImmunologyVol. 17
University Medical Center Groningen (NL), University of Groningen (NL)
Universitair Medisch Centrum Groningen
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon